Synapse - Neeta Pandit-Taskar

Results (65)

Computational nuclear oncology toward precision radiopharmaceutical therapies: Current tools, techniques, and uncharted territories

Review

Yusufaly, T.; Roncali, E.; Brosch-Lenz, J.; Uribe, C.; Jha, A. K.; Currie, G.; Dutta, J.; El-Fakhri, G.; McMeekin, H.; Pandit-Taskar, N.; more...
Journal of Nuclear Medicine (2025)

Fulltext@MSK | Save

Survival outcomes and dosimetric analysis of Iomab-B (131I-apamistamab) followed by allogeneic hematopoietic cell transplant for patients with TP53 mutated relapsed/refractory AML

Meeting Abstract

Natwa, M.; Leung, E.; Chen, M. K.; Wagner, R.; Yap, W.; Griffeth, L.; Wiseman, G.; Wahl, R.; Avril, N.; Lamonica, D.; more...
Journal of Nuclear Medicine (2024)

Fulltext@MSK | Save

Exploratory analysis of bone marrow dosimetry from the randomized phase 3 SIERRA trial of Iomab-B (131I-apamistamab) prior to HCT in relapsed/refractory acute myeloid leukemia

Meeting Abstract

Pandit-Taskar, N.; Natwa, M.; Chen, M. K.; Wagner, R.; Yap, W.; Griffeth, L.; Wiseman, G.; Passalaqua, S.; Avril, N.; Lamonica, D.; more...
Journal of Nuclear Medicine (2024)

Fulltext@MSK | Save

Computational nuclear oncology for precision radiopharmaceutical therapies

Meeting Abstract

Yusufaly, T.; Roncali, E.; Uribe, C.; Shi, K. Y.; Bradshaw, T.; Jha, A.; Strigari, L.; Currie, G.; McMeekin, H.; Schwartz, J.; more...
Journal of Nuclear Medicine (2024)

Fulltext@MSK | Save

Mathematical modeling of exposure measurements following high-dose targeted therapy using 131I-apamistamab: Analysis from the large multicenter phase III SIERRA trial

Meeting Abstract

Pandit-Taskar, N.; Chen, L. Y.; Serencsits, B.; Prasad, K.; Senglaub, T.; Zgaljardic, M.; Spross, J.; Desai, A.; Brodin, P.
Journal of Nuclear Medicine (2024)

Fulltext@MSK | Save

Theranostic intratumoral convection-enhanced delivery of (124)I-omburtamab in patients with diffuse intrinsic pontine glioma: Pharmacokinetics and lesion dosimetry

Journal Article

Pandit-Taskar, N.; Zanzonico, P. B.; Grkovski, M.; Donzelli, M.; Vietri, S. M.; Horan, C.; Serencsits, B.; Prasad, K.; Lyashchenko, S.; Kramer, K.; more...
Journal of Nuclear Medicine (2024)

Fulltext@MSK | Save

A phase 0 study to assess the biodistribution and pharmacokinetics of a radiolabeled antibody targeting human kallikrein 2 in participants with metastatic castration-resistant prostate cancer

Journal Article

Pandit-Taskar, N.; O'Donoghue, J. A.; Chetty, D.; Max, S.; Wanik, D.; Ilovich, O.; Russell, M.; Nyima, T.; Divgi, C. R.; Yu, M.; more...
Journal of Nuclear Medicine (2024)

Fulltext@MSK | Save

(18)F-BMS-986229 PET to assess programmed-death ligand 1 status in gastroesophageal cancer

Journal Article

Cytryn, S. L.; Pandit-Taskar, N.; Lumish, M. A.; Maron, S. B.; Gu, P.; Ku, G. Y.; Chou, J. F.; Capanu, M.; Antoine, A.; Loegel, D.; more...
Journal of Nuclear Medicine (2024)

Fulltext@MSK | Save

Individualized dosing for high-dose targeted radiation of hematopoietic cells with Iomab-B (I131-apamistamab) prior to HCT in relapsed/refractory acute myeloid leukemia (R/R AML): Safety and efficacy results from the pivotal phase 3 SIERRA trial

Meeting Abstract

Pandit-Taskar, N.; Natwa, M.; Chen, M. K.; Wagner, R.; Yap, W.; Griffeth, L.; Wiseman, G.; Mhlanga, J.; Wahl, R.; Avril, N.; more...
Journal of Nuclear Medicine (2023)

Fulltext@MSK | Save

89Zr-DFO-girentuximab PET/CT imaging can accurately detect clear cell renal cell carcinoma primary and secondary lesions in patients with renal masses at conventional imaging, results from ZIRCON phase 3 study

Meeting Abstract

Calais, J.; Shuch, B.; Pantuck, A.; Bernhard, J. C.; Morris, M.; Master, V.; Scott, A.; van Praet, C.; Bailly, C.; Aksoy, T.; more...
Journal of Nuclear Medicine (2023)

Fulltext@MSK | Save